FDA Grants Approval for Durvalumab in Treating Resectable Adenocarcinoma of the Stomach or Gastroesophageal Junction

FDA Grants Approval for Durvalumab in Treating Resectable Adenocarcinoma of the Stomach or Gastroesophageal Junction

FDA Grants Approval for Durvalumab in Treating Resectable Adenocarcinoma of the Stomach or Gastroesophageal Junction